Prosecution Insights
Last updated: August 06, 2026
Application No. 18/010,864

SMALL MOLECULE COVALENT ACTIVATORS OF UCP1

Non-Final OA §102
Filed
Dec 16, 2022
Priority
Jun 16, 2020 — provisional 63/039,643 +2 more
Examiner
SZNAIDMAN, MARCOS L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dana-Farber Cancer Institute Inc.
OA Round
2 (Non-Final)
37%
Grant Probability
At Risk
2-3
OA Rounds
0m
Est. Remaining
53%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
472 granted / 1268 resolved
-22.8% vs TC avg
Strong +16% interview lift
Without
With
+16.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
56 currently pending
Career history
1329
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
38.3%
-1.7% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
28.1%
-11.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1268 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to applicant’s reply filed on March 9, 2026. Status of Claims Amendment of claims 1, 17, 32 and 49 is acknowledged. Claims 1, 11, 14, 17-18, 28-29, 32-33, and 41-49 are currently pending and are the subject of this office action. Claims 35 and 38 were withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on September 17, 2025. Due to Applicant amendments, the previously examined species: PNG media_image1.png 168 298 media_image1.png Greyscale no longer anticipates the claims. As such, the examination was expanded to the following species: PNG media_image2.png 230 506 media_image2.png Greyscale So, the following species are under examination: PNG media_image3.png 110 124 media_image3.png Greyscale elected by Applicant, which is free of prior art, and PNG media_image2.png 230 506 media_image2.png Greyscale expanded species. The following claims read on the elected species: 1, 11, 14, 17-18, 28-29, 32-33, 41 and 44-46. The following claims read on the expanded species: 1, 11, 14, 17-18, 29, 33 and 41. The combined set of claims that read on one or both species and, therefore, are presently under examination are: 1, 11, 14, 17-18, 28-29, 32-33, 41 and 44-46. Claims 42-43 and 47-49 are further withdrawn since they don’t read on any of the above species Priority PNG media_image4.png 64 370 media_image4.png Greyscale Rejections and/or Objections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Rejections and/or Objections) or newly applied (New Rejections and/or Objections, Necessitated by Amendment or New Rejections and/or Objections not Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. Responses to Applicant’s arguments have been addressed immediately after the corresponding rejections, or in the section: Withdrawn Rejections and/or Objections, if the rejection was withdrawn. Claim Rejections - 35 USC § 102 (New Rejection Necessitated by Amendment) In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 11, 14, 17-18, 29, 33 and 41 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Liang et. al. (European Journal of Medicinal Chemistry (2017) 131:107-125). For claims: 1, 11, 14, 17-18, 29, 33 and 41, Liang teaches the following compound (compound 35, see page 111, Scheme 4; and see page 113, Table 3): PNG media_image2.png 230 506 media_image2.png Greyscale Wherein the compound anticipates formula (Ia), wherein: Ra = Rb = Rc =H, L1 = L2 = bond, L3 = -NH X = O R1 = alkyl (methyl), and R2 = substituted heterocycloalkenyl. Claim Objections Claims 28, 32 and 44-46 are objected to in part, but only insofar as it relates to the applicant elected species which has been found to be free of prior art, as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim, any intervening claims, and to recite only the elected species. Note that claims 28, 32 and 44-46 are objected to in part herein insofar as it contains non-elected subject matter to which the prior art search has not yet been extended. That part which has been searched, however (consistent with the election of species requirement as previously discussed), would be allowable if the claim was amended in independent form including all the limitations of the base claim and any intervening claims, and to remove the currently non-elected subject matter (i.e. all the species except for PNG media_image3.png 110 124 media_image3.png Greyscale ). Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 March 12, 2026.
Read full office action

Prosecution Timeline

Dec 16, 2022
Application Filed
Dec 18, 2025
Non-Final Rejection mailed — §102
Mar 09, 2026
Response Filed
May 18, 2026
Final Rejection mailed — §102
Jul 14, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697389
USE OF DIKETONE COMPOUND IN PHOTODYNAMIC THERAPY OR DIAGNOSIS
4y 8m to grant Granted Aug 04, 2026
Patent 12692234
ROCK INHIBITORS AND USES THEREOF
1y 1m to grant Granted Jul 28, 2026
Patent 12685725
PRIDOPIDINE FOR THE TREATMENT OF MITOCHONDRIAL-ASSOCIATED DISEASES AND DISORDERS AND ENDOPLASMIC RETICULUM (ER) STRESS
5y 4m to grant Granted Jul 21, 2026
Patent 12667556
EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF
5y 1m to grant Granted Jun 30, 2026
Patent 12667559
DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
3y 10m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
37%
Grant Probability
53%
With Interview (+16.0%)
3y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1268 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month